PHC Holdings Corporation completed the acquisition of Anatomical Pathology business from Thermo Fisher Scientific Inc..
June 28, 2019
Share
PHC Holdings Corporation signed a definitive agreement to acquire Anatomical Pathology business from Thermo Fisher Scientific Inc. (NYSE:TMO) for approximately $1.1 billion on January 28, 2019. Anatomical Pathology Business is a part of Thermo Fisher's Specialty Diagnostics Segment. The business generated approximately $344 million revenues in 2018. Transaction is subject to customary closing conditions and applicable regulatory approvals. Transaction is expected to close in the second quarter of 2019. The company expects the net dilution to 2019 adjusted earnings per share to be approximately $0.10. Katie Sudol, Johanna Mayer, Makiko Harunari, Shahpur Kabraji, Atsushi Usui, Tomohiro Koyasu, Katharine Moir, Joseph Tootle, Dmitry Zelik, Tristan Brown, Alyssa Ohanian, Erik Ward, Lori Lesser, Alysha Sekhon, Adeeb Fadil, Noreen Lavan, David Vann, Noritaka Kumamoto, Etienne Renaudeau, Megan Griffith, Krista McManus, Dennis Loiacono, Steve DeLott and Janet Kyung-Ah Yu of Simpson Thacher & Bartlett Llp acted as legal advisor to PHC Holdings Corporation. Hal Leibowitz, Joe Conahan, Andrew Langworthy, Robert Burke, Ciara Baker, John Sigel, Justin Ochs, Amy Null, Scott Kilgore, Ashwin Gokhale, Christian Crones, Lester Ross and Jasmine Haddad of Wilmer Cutler Pickering Hale and Dorr LLP acted as legal advisor for Thermo Fisher Scientific Inc. Paul Parker, Chuck Adams, Marc Schaffer, Caitlin Pollak and Brian McMahon of Goldman Sachs & Co. LLC acted as financial advisor for Thermo Fisher Scientific Inc. J.P. Morgan acted as financial advisor to PHC Holdings. Jan Balssen, Christian Cascante, Michael Ilter, Konstantin von Dryander, Andrej Popp, Marco König, Oliver Jürgen Junge, Doris-Maria Schuster, Sebastian Schulte, Frank Schlobach, Alexander Molle, Hannah Bug, Anna Karpf, Ingo Brinker, Iris Benedikt-Buckenleib, Jacob von Andreae, Aylin Hoffs, Stefan Mayer, Ocka Stumm and Philipp Naab of Gleiss Lutz acted as legal advisor to PHC Holdings.
PHC Holdings Corporation completed the acquisition of Anatomical Pathology business from Thermo Fisher Scientific Inc. (NYSE:TMO) on June 28, 2019. The acquired Anatomical Pathology business will operate as a new stand-alone company named Epredia.
PHC Holdings Corp is a Japan-based company mainly engaged in the development, manufacture and sale of healthcare devices and services. The Company operates through three business segments. The Diabetes Management segment is involved in the development, manufacture and sale of in vitro diagnostic equipment such as self-monitoring blood glucose systems and point-of-care testing (POCT) products and electric drug injectors. The Healthcare Solutions segment is involved in the development and sale of medical information technology (IT) products such as receipt computers and electronic medical records, as well as the development of clinical laboratory diagnosis business. The Diagnostic and Life Science segment is involved in the development, manufacture and sale of research and medical support equipment, pathological diagnosis equipment, among others.
PHC HOLDINGS CORPORATION 
